Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Obesity in Newly Diagnosed Childhood Acute Promyelocytic Leukemia.

James Feusner, MD, Haesook Kim, PhD, John Gregory, MD, Todd Alonzo, PhD, William Woods, MD, Howard Weinstein, MD, Martin Tallman, MD

Blood (2006) 108 (11): 4494.

https://doi.org/10.1182/blood.V108.11.4494.4494

Published: 2006

Journal Articles

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421

David Becton, Gary V. Dahl, Yaddanapudi Ravindranath, Myron N. Chang, Fred G. Behm, Susana C. Raimondi, David R. Head, Kimo C. Stine, Norman J. Lacayo, Branimir Ivan Sikic, Robert J. Arceci, Howard Weinstein

Blood (2006) 107 (4): 1315–1324.

https://doi.org/10.1182/blood-2004-08-3218

Published: 2006

Journal Articles

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman Lacayo, MD, Soheil Meshinchi, MD, Susana Raimondi, PhD, Chitra Saraiya, MS, Maureen O’Brien, MD, Ronald Yu, PhD, Dejan Juric, MD, Myron Chang, PhD, Cheryl Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir Sikic, MD, Howard Weinstein, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2372.

https://doi.org/10.1182/blood.V106.11.2372.2372

Published: 2005

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

Journal Articles

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Steven Buck, MS, Ron Yu, MA, Chitra Saraiya, MS, Lorrie Douglas, BS, Howard Weinstein, MD, Myron Chang, MD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Gary V. Dahl, MD, Branimir Sikic, MD, Yaddanapudi Ravindranath, MD

Blood (2004) 104 (11): 1130.

https://doi.org/10.1182/blood.V104.11.1130.1130

Published: 2004

Journal Articles

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Norman J. Lacayo, MD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Dennis J. Kuo, MD, Ron Yu, MA, Myron N. Chang, PhD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir I. Sikic, MD, Howard Weinstein, MD, Gary V. Dahl, MD

Blood (2004) 104 (11): 570.

https://doi.org/10.1182/blood.V104.11.570.570

Published: 2004

Journal Articles

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred G. Behm, MD, Myron Chang, PhD, Howard Weinstein, MD

Blood (2004) 104 (11): 616.

https://doi.org/10.1182/blood.V104.11.616.616

Published: 2004

Journal Articles

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

Norman J. Lacayo, Soheil Meshinchi, Paivi Kinnunen, Ron Yu, Yan Wang, Christianna M. Stuber, Lorrie Douglas, Romina Wahab, David L. Becton, Howard Weinstein, Myron N. Chang, Cheryl L. Willman, Jerald P. Radich, Robert Tibshirani, Yaddanapudi Ravindranath, Branimir I. Sikic, Gary V. Dahl

Blood (2004) 104 (9): 2646–2654.

https://doi.org/10.1182/blood-2003-12-4449

Published: 2004

Journal Articles

All- trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.

Martin S. Tallman, Janet W. Andersen, Charles A. Schiffer, Frederick R. Appelbaum, James H. Feusner, William G. Woods, Angela Ogden, Howard Weinstein, Lois Shepherd, Cheryl Willman, Clara D. Bloomfield, Jacob M. Rowe, Peter H. Wiernik

Blood (2002) 100 (13): 4298–4302.

https://doi.org/10.1182/blood-2002-02-0632

Published: 2002

NARROW

Obesity in Newly Diagnosed Childhood Acute Promyelocytic Leukemia.

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

All- trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only